Going Out With a Bang--An Interview with Ron Dollens
Executive Summary
Few companies have achieved the kinds of success that Guidant Corp. has in its ten years in existence and few executives have had the impact on the medical device space that Ron Dollens, Guidant's CEO, has had. In this interview, adapted from the Stanford BioDesign Program's "From the Innovator's Work Bench" series, Dollens talks about his career and about the success Guidant has had.
You may also be interested in...
Beyond Medical Devices: An Interview with Medtronic's Bill Hawkins
In a career that has spanned more than 20 years, Bill Hawkins has worked for a wide array of medical device firms, leaving his imprint on this industry. Now, as Medtronic's COO, his influence will only grow. In this interview, Hawkins talks about the history of the device industry and what lies ahead.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.